Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
|
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 50 条
  • [41] Cortical structure and the risk for Alzheimer’s disease: a bidirectional Mendelian randomization study
    Bang-Sheng Wu
    Ya-Ru Zhang
    Hong-Qi Li
    Kevin Kuo
    Shi-Dong Chen
    Qiang Dong
    Yong Liu
    Jin-Tai Yu
    Translational Psychiatry, 11
  • [42] Cortical structure and the risk for Alzheimer's disease: a bidirectional Mendelian randomization study
    Wu, Bang-Sheng
    Zhang, Ya-Ru
    Li, Hong-Qi
    Kuo, Kevin
    Chen, Shi-Dong
    Dong, Qiang
    Liu, Yong
    Yu, Jin-Tai
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [43] Impact of Serum Calcium Levels on Alzheimer's Disease: A Mendelian Randomization Study
    He, Yating
    Zhang, Haihua
    Wang, Tao
    Han, Zhifa
    Ni, Qing-bin
    Wang, Kun
    Wang, Longcai
    Zhang, Yan
    Hu, Yang
    Jin, Shuilin
    Sun, Bao-liang
    Liu, Guiyou
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 76 (02) : 713 - 724
  • [44] Polyunsaturated fatty acids and risk of Alzheimer’s disease: a Mendelian randomization study
    Yasutake Tomata
    Susanna C. Larsson
    Sara Hägg
    European Journal of Nutrition, 2020, 59 : 1763 - 1766
  • [45] Circulating vitamin E levels and Alzheimer's disease: a Mendelian randomization study
    Liu, Guiyou
    Zhao, Yi
    Jin, Shuilin
    Hu, Yang
    Wang, Tao
    Tian, Rui
    Han, Zhifa
    Xu, Dandan
    Jiang, Qinghua
    NEUROBIOLOGY OF AGING, 2018, 72 : 189.e1 - 189.e9
  • [46] Impact of diabetes mellitus on the risk of Alzheimer's disease: a mendelian randomization study
    Wang, Weichao
    Zhang, Jie
    Zhang, Man
    Zhang, Chengyuan
    Liu, Huanli
    Li, Wanlin
    Fan, Yimeng
    BMC NEUROLOGY, 2024, 24 (01)
  • [47] Authors' response to: A Mendelian randomization study of Alzheimer's disease and daytime napping
    Li, Peng
    Gao, Lei
    Dashti, Hassan S.
    Hu, Kun
    Leng, Yue
    ALZHEIMERS & DEMENTIA, 2024, 20 (01) : 743 - 744
  • [48] Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study
    Andrews, Shea J.
    Goate, Alison
    Anstey, Kaarin J.
    ALZHEIMERS & DEMENTIA, 2020, 16 (02) : 345 - 353
  • [49] Social Isolation, Social Interaction, and Alzheimer's Disease: A Mendelian Randomization Study
    Shen, Ling-Xiao
    Yang, Yu-Xiang
    Kuo, Kevin
    Li, Hong-Qi
    Chen, Shi-Dong
    Chen, Ke-Liang
    Dong, Qiang
    Tan, Lan
    Yu, Jin-Tai
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 80 (02) : 665 - 672
  • [50] ASSESSING THE EFFECT OF ANTIHYPERTENSIVE DRUGS ON SYSTEMIC LUPUS ERYTHEMATOSUS: A MENDELIAN RANDOMIZATION STUDY
    Lu, Y.
    Zhao, Z.
    Song, S.
    Qiao, J.
    Zhang, S. X.
    Li, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1065 - 1065